Clinical Use of Biomarkers in Cardiac Amyloidosis.
Heart Fail Clin
; 20(3): 283-294, 2024 Jul.
Article
in En
| MEDLINE
| ID: mdl-38844299
ABSTRACT
Amyloidosis is a systemic condition characterized by multiple organs involvement. A multidisciplinary and multimodal approach in assessing patients is pivotal and recommended by the international scientific societies. Biomarkers represent an essential noninvasive tool to increase the suspicion of disease and orient further workup and clinical management of patients. This review provides an updated contemporary focus on the clinical use of biomarkers in cardiac amyloidosis, emphasizing their role in both the diagnostic and prognostic setting and discussing future perspective of emerging biomarkers.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Biomarkers
/
Amyloidosis
/
Cardiomyopathies
Limits:
Humans
Language:
En
Journal:
Heart Fail Clin
Year:
2024
Document type:
Article